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Background: Tumor associated macrophages (TAMs) are alternatively activated macrophages that enhance tumor
progression by promoting tumor cell invasion, migration and angiogenesis. TAMs have an anti-inflammatory
function resembling M2 macrophages. CD163 is regarded as a highly specific monocyte/macrophage marker for
M2 macrophages. In this study we evaluated the specificity of using the M2 macrophage marker CD163 as a TAM
marker and compared its prognostic value with the more frequently used pan-macrophage marker CD68. We also
analyzed the prognostic value of the localization of CD163+ and CD68+ myeloid cells in human breast cancer.
Methods: The extent of infiltrating CD163+ or CD68+ myeloid cells in tumor nest versus tumor stroma was
evaluated by immunohistochemistry in tissue microarrays with tumors from 144 breast cancer cases. Spearman’s
Rho and χ2 tests were used to examine the correlations between CD163+ or CD68+ myeloid cells and
clinicopathological parameters. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess
the impact of CD163+ and CD68+ myeloid cells in tumor stroma and tumor nest, respectively, on recurrence free
survival, breast cancer specific and overall survival.
Results: We found that infiltration of CD163+ and CD68+ macrophages into tumor stroma, but not into tumor nest,
were of clinical relevance. CD163+ macrophages in tumor stroma positively correlated with higher grade, larger
tumor size, Ki67 positivity, estrogen receptor negativity, progesterone receptor negativity, triple-negative/basal-like
breast cancer and inversely correlated with luminal A breast cancer. Some CD163+ areas lacked CD68 expression,
suggesting that CD163 could be used as a general anti-inflammatory myeloid marker with prognostic impact.
CD68+ macrophages in tumor stroma positively correlated to tumor size and inversely correlated to luminal A
breast cancer. More importantly, CD68 in tumor stroma was an independent prognostic factor for reduced breast
cancer specific survival.
Conclusion: These findings highlight the importance of analyzing the localization rather than merely the presence
of TAMs as a prognostic marker for breast cancer patients.
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A malignant tumor is comprised of cancer cells and the
tumor microenvironment. The tumor microenvironment
consists of extracellular matrix, endothelial cells, fibro-
blasts and leukocytes, all of which influence the fate of
cancer cells and hence the clinical outcome. Tumor
associated macrophages (TAMs) have been shown to en-
hance tumor progression by promoting tumor invasion,
migration and angiogenesis [1]. TAMs, which are often
abundantly present in malignant tumors, share many
common features with the alternatively activated anti-
inflammatory macrophages (M2) [2].
Macrophages can be differentiated into either pro-
inflammatory M1 macrophages or anti-inflammatory
M2 macrophages. M1 macrophages activate type 1
helper T cells (Th1), have the ability to kill pathogens
and are tumoricidal. M2 macrophages on the other hand
are involved in wound healing where they downregulate
the inflammatory reactions, promote angiogenesis, re-
cruit fibroblasts and regulate connective tissue remodel-
ing. Furthermore, M2 macrophages have a weak
tumoricidal capability [3].
CD163 is a scavenger receptor upregulated by macro-
phages in an anti-inflammatory environment [4] and
regarded as a highly specific monocyte/macrophage mar-
ker for M2 macrophages [5-7].
In 2002 Bingle et al. reported that the majority of pub-
lications on TAMs in cancer (including breast cancer)
reported a correlation between high TAM infiltration
and poor patient outcome [8-11]. All papers in the
metaanalysis except one (which used CD31 and thymi-
dine phosphorylase) used CD68 as a marker for TAMs
[8]. However CD68, unlike CD163, recognizes both M1
and M2 macrophages [12]. To our knowledge CD163
has not been evaluated as a TAM marker in primary
breast cancer. Therefore, the aim of this study was to
analyze whether CD163 can be used as a marker for
TAMs and to compare its prognostic value with the
more frequently used pan-macrophage marker CD68 in
a tissue microarray (TMA) with tumors from 144 breast
cancer patients.
In melanoma, the presence of TAMs in the tumor
stroma (TS) correlated with poor overall survival (OS)
[13], while contrasting data have been reported for colo-
rectal cancer [14]. We therefore aimed to examine the
importance of localization of TAMs on tumor-
promoting capabilities and whether localization in the
TS or tumor nest (TN) is of prognostic relevance in
breast cancer.
Here we show that infiltration of CD163+ and CD68+
macrophages into TS, but not TN, is of clinical rele-
vance for breast cancer patients. This highlights the im-
portance of analyzing the localization rather than merely
the presence of TAMs as a prognostic marker. While thepresence of CD163+ macrophages in TS was more
strongly associated with less favorable clinicopathologi-
cal features, CD68+ macrophages in TS was a significant




The breast cancer cohort analyzed consists of 144
patients diagnosed with invasive breast cancer at Skåne
University Hospital, Malmö, Sweden, between 2001 and
2002. The cohort and TMA construction have previ-
ously been described in detail [15-17]. The majority,
109, of the patients had luminal A breast cancer (79%),
while 15 patients (11%) had triple-negative/basal-like
breast cancer. Immunohistochemical staining of ER, PR,
and human epidermal growth factor receptor (HER) was
performed as previously described [18] and used as sur-
rogate markers for molecular subtypes [19]. Mean age
was 65 years (range 34-97). During follow-up, 41 patients
(28%) died and 29 patients (20%) had recurrence. Median
follow-up was 6.55 years (range 0.33-7.55 years) for the
full cohort and 6.74 years (range 4.88-7.55) for patients
alive. Ninety-six patients (67%) had endocrine therapy: of
whom 3 patients (2%) had been given aromatase inhibi-
tors (AI) only, 67 (47%) tamoxifen only and 25 patients
(17%) both AI and tamoxifen, and in 1 (1%) case unspeci-
fied. Of the 30 patients (21%) receiving chemotherapy,
26 (87%) had a combined treatment with fluorouracil,
epirubicin and cyclophosphamide (FEC). Ethical ap-
proval for the use of breast cancer specimens for this
study was obtained from the Ethics Committee at Lund
University (ref no 447-07), whereby written consent was
not required and patients were offered the option to
opt out.
Immunohistochemistry
Four μm thick TMA sections were mounted onto glass
slides and deparaffinised followed by antigen retrieval
using the PT-link system (DAKO, Glostrup, Denmark)
and then stained in an Autostainer Plus (DAKO) with
the EnVisionFlex High pH-kit (DAKO). Primary anti-
bodies included: anti-CD163 (10D6 dilution 1:250;
Novocastra), anti-CD68 (dilution 1:1500; DAKO) and
anti-DC-LAMP (also known as CD208; a marker for
mature myeloid dendritic cells; clone 101E1.01 dilution
1:1000; Dendritics). Immunohistochemistry (IHC) had
previously been performed on sections from the same
TMA blocks with the anti-Granulin antibody
HPA028747 (expressed in tumor-resident bone marrow
derived cells responsible for instigation; 1:100; AtlasAn-
tibodies) and the outcome of immunoreactivity was
assessed by image analysis [15]. The estimated fraction
of cells with nuclear Ki67 expression was denoted as low
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ing to previous studies [20]. ER-negativity and PR-
negativity was defined as <10% positively staining nu-
clei, according to current clinical guidelines in Sweden.
The CD163 and CD68 staining was scored as the infil-
tration density of CD163+ and CD68+ cells with a mono-
cyte/macrophage morphology, ranging from 0 (absent)
up to 3 (dense). For statistical analyses, these categories
were dichotomized into absent/sparse (0-2) or dense (3)
macrophage infiltration. The CD163+ and CD68+ macro-
phages were scored in the TS and TN separately. The
amount of TS content was scored into the categories
≤50% or >50% of the tumor core as visualized by HE-
staining and microscopic evaluation. The CD208/DC-
LAMP staining was scored as the presence of CD208+
cells with a DC morphology ranging from 0 (absent) – 1




Figure 1 IHC staining of primary breast tumors. CD163+ A, B and CD68
and TN. CD208+ cells were located in peri-tumoral T cell zones only, E. Gen
using the microarray profile set [GenBank:GDS1329] [21] from NCBI Gene Ecases (31 out of 121) and were located in the peri-
tumoral T cell rich areas only.
Gene expression analysis
The gene expression levels of CD163 and CD68 in dif-
ferent breast cancer patient groups were analyzed using
microarray profile sets, [GenBank:GDS1329] [21] and
[GenBank:GDS806] [22], from NCBI Gene Expression
Omnibus profiles [23].
Statistics
Spearman’s Rho and χ2 tests were used for comparison
of CD163 and CD68 expression and patient and tumor
characteristics. Kaplan-Meier analysis and log rank tests
were used to illustrate differences in recurrence free sur-
vival (RFS), breast cancer specific survival (BCSS) and


























+ C, D, cells with a macrophage-morphology were present in both TS
e expression levels of CD163 in luminal and basal-like breast cancer,
xpression Omnibus profiles, F. *** P<0.001.
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were used for estimation of hazard ratios (HR) for death
from breast cancer or overall causes according to CD163
and CD68 expression in both uni- and multivariable
analysis. Covariates with a P value ≤ .05 in the univari-
able analysis were included in the multivariable analysis.
All statistical tests were two sided and P ≤ .05 was con-
sidered significant. Calculations were performed with
IBM SPSS Statistics version 19.0 (SPSS Inc).
For the gene expression data, the means, standard
deviations and standard error of the means were ana-
lyzed and plotted with GraphPad Prism software. Statis-
tical analyses were carried out with unpaired Student’s
t-test.Results
Characterization of CD163+ and CD68+ macrophages in
primary breast cancer
Due to loss of material or low tumor cell content, 121
(84%) samples were annotated for CD163 in TS, 105
(73%) for CD163 in TN and 108 (75%) samples were
scored for CD68 in both TS and TN. As shown in
Figure 1A-D, CD163+ and CD68+ cells with a
macrophage-morphology were present in both TS and
TN of primary breast cancers. There was a strong cor-
relation between CD163 and CD68 in both TS (P<.001)
and TN (P<.001). There was no correlation between the
infiltration density of macrophages in TS and the infil-
tration density of macrophages in the TN. However,
CD163 in TN correlated to the presence of CD208+ cells
in peri-tumoral T cell zones (P= .009). CD208 (DC-
LAMP) is a marker for mature myeloid dendritic cells
(MDC), which could be reasoned to express CD163 [24].
CD208+ cells were only found in the T cell rich peri-
tumoral areas and not in TN (Figure 1E).Distribution of CD163+ and CD68+ macrophages in
primary breast cancer
To analyze if the localization of CD163+ and CD68+
macrophages had any correlation to clinical characteris-
tics, the distribution of CD163+ and CD68+ macro-
phages in TS and TN was evaluated separately (Table 1
and see Additional file 1). The staining categories ini-
tially scored from 0 to 3 in macrophage infiltration dens-
ity were further dichotomized into two groups with
absent/sparse (0-2) or dense (3) macrophage infiltration.
Seventeen percent of the tumors were denoted as having
dense infiltration of CD163+ macrophages in TS, while
9% had dense infiltration in TN. Nine percent had dense
infiltration of CD68+ macrophages in TS, while 6% had
dense infiltration in TN. Hence, the majority of tumors
had absent or sparse macrophage infiltration.Distribution of CD163+ and CD68+ macrophages in
luminal a and triple-negative/basal-like breast cancer
CD163+ and CD68+ macrophages were more equally
distributed among the patients with luminal A breast
cancer (see Additional file 1). The majority had absent/
sparse macrophage infiltration density in both the TS
and TN. Dense infiltration of CD163+ and CD68+
macrophages in TS was observed in only 8% and 6% of
the cases respectively. Eighty percent of the triple-
negative/basal-like breast cancer patient had dense infil-
tration of CD163+ macrophages in TS, while 23% had
dense infiltration of CD68+ macrophages in TS. This
was not due to an increase in the amount of TS since
we saw an inverse correlation between the amount of TS
and the density of TS-associated CD163+ and CD68+
TAMs (see Additional file 2). We did not find any cor-
relation between the amount of TS and breast cancer
subtypes in our cohort (data not shown). The majority
of the cases (92% for CD163+ and 100% for CD68+) had
absent/sparse macrophage infiltration in TN.Correlations between CD163+ and CD68+ macrophages
and clinicopathological characteristics
Breast cancer tumors with dense infiltration of CD163+
macrophages in the TS were of higher grade (P<.001),
larger size (P<.001) and had a higher proliferation index
as indicated by Ki67 positivity (P= .007). Dense infiltra-
tion of CD163+ macrophages in the TS was further asso-
ciated with estrogen receptor (ER) negativity (P= .001),
progesterone receptor (PR) negativity (P<.001), triple-
negative/basal-like breast cancer (P<.001), inversely cor-
related with luminal A breast cancer (P<.001) (Table 1)
and correlated with the extent of granulin (GRN)
expression (P= .01) (see Additional file 3). CD163+
macrophages in TN did not correlate with any clinico-
pathological features.
To further evaluate the association between CD163+
macrophages and different breast cancer subtypes, we
analyzed the gene expression levels of CD163 in both
basal-like and luminal breast cancer, using a publically
available gene expression array dataset [GenBank:
GDS1329] [21] from NCBI Gene Expression Omnibus
profiles [23]. In line with the findings from the TMA-
based analysis, basal-like breast cancer had significantly
higher gene expression levels of CD163 (P<.001) com-
pared to luminal breast cancer (Figure 1F), but also of
CD68 (P<.05) (data not shown).
Dense infiltration of CD68+ macrophages in the TS
positively correlated with large tumor size and high
grade and inversely correlated with luminal A breast
cancer. There was no significant association between
CD68+ macrophages in TN and any clinicopathological
features.























Age −0.011 .91 121 0.027 .79 105 0.227* .02 108 −0.114 .24 108
Nodal stage 0.094 .33 108 −0.163 .12 95 0.18 .08 98 −0.008 .94 97
Tumor size 0.339** .000 121 0.031 .75 105 0.250** .009 108 0.033 .74 108
Ki67 0.263** .007 104 0.127 .23 91 0.131 .21 92 0.05 .65 92
NHG 0.326** .000 121 0.091 .35 105 0.272** .004 108 0.024 .81 108
Her 2 −0.024 .80 117 −0.077 .44 103 0.079 .42 104 −0.06 .54 104
ER status −0.422** .000 121 −0.069 .48 105 −0.047 .63 108 0.11 .26 108
PR status −0.395** .000 121 0.066 .50 105 −0.045 .64 108 0.106 .27 108
Basal 0.621** .000 118 −0.014 .89 103 0.173 .08 104 −0.102 .31 104
Triple negative 0.624** .000 118 −0.014 .89 103 0.173 .08 104 −0.102 .31 104
Luminal A −0.514** .000 114 0.076 .45 100 −0.237* .02 100 0.141 .16 100
Luminal B 0.034 .72 116 −0.054 .59 102 0.138 .17 102 −0.047 .64 102
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We found that dense infiltration of CD163+ and in par-
ticular CD68+ macrophages in TS correlated with poor
OS (Figure 2A-D and Table 2) and poor BCSS (Table 2).
CD68+ macrophages in TS further correlated to recur-
rence (Figure 3A and Table 2). Using a publically avail-
able gene expression array dataset [GenBank:GDS806]
[22] from NCBI Gene Expression Omnibus profiles [23]
we were able to identify that breast cancer patients re-
ceiving endocrine therapy, who had recurrence, had sig-
nificantly higher gene expression levels of CD68
(Figure 3B).
There was no observed correlation between CD163+
or CD68+ macrophages in TN with OS, BCSS or RFS
(Table 2).
Since CD163+ macrophages in the TS positively corre-
lated with triple-negative/basal-like breast cancer and in-
versely correlated with luminal A breast cancer (Table 1
and 2), the prognostic value of CD163+ macrophages in TS
was evaluated separately in the two different breast cancer
subtypes (Figure 4A, B). Luminal A breast cancer patients
with dense infiltration of CD163+ macrophages had a worse
OS (Figure 4A). The majority (74%) of the luminal A breast
cancer patients received endocrine therapy.
There was no difference in patient outcome according to
CD163+ macrophage infiltration in TS in the triple-negative
/basal-like breast cancer patient group (Figure 4B).
Multivariate analyses revealed that CD163 was not an
independent risk factor for OS, BCSS or RFS (Table 3).
Dense infiltration of CD68+ macrophages in TS was not
an independent risk factor for OS and RFS but was an
independent risk factor for BCSS (HR= 0.12; 95% CI,
0.02 to 0.72; P= .02), (Table 3).Discussion
CD68 is a pan-macrophage marker frequently used as a
marker for TAMs. However, CD68 recognizes both
tumoricidal M1 and anti-inflammatory M2 macro-
phages. This may explain previous contradictory data
showing that dense infiltration of TAMs was correlated
to both good and poor patient outcome [8]. CD163 is a
highly specific monocyte/macrophage marker that has
recently been suggested to be expressed primarily by the
anti-inflammatory subtypes of macrophages [4-7,25]. In
this study we aimed to compare CD163 with the more
frequently used pan-macrophage marker CD68. In
addition we analyzed if the localization of macrophages
in primary breast cancer could be of clinical relevance.
In our patient cohort, infiltration of TAMs in the TN
was not correlated with any clinicopathological features
and did not relate to OS, BCSS or RFS. The involvement
of TN located TAMs for patient outcome should not
however be fully excluded. In melanoma, for instance
CD68+ TAMs in the TN positively correlated with both
poor OS and RFS, however it did not fall out as an inde-
pendent risk factor upon multivariate analysis [13]. In
endometrial cancer and gastric cancer, dense infiltration
of CD68+ cells in the TN positively correlated with fewer
recurrences [26,27] and hence suggested a beneficial ef-
fect of TAMs in the TN.
In our study, dense infiltration of CD163+ macro-
phages located in TS correlated with grade, tumor size,
subtypes and receptor status. In line with previous
papers reporting that the content of TAMs inversely cor-
relates with ER expression in breast cancer [28,29],
CD163+ macrophages located in TS correlated with ER
negativity. Furthermore, CD163+ macrophages in TS
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Figure 2 OS according to the infiltration density of CD163+ and CD68+ cells in primary breast cancer. OS curves according to the
infiltration density of CD163+ and CD68+ cells in TS. Non grouped data A,B. Grouped data C,D,E,F. OS curves according to the infiltration density
of CD163+ and CD68+ cells in TS C,D and TN E,F.
Table 2 Univariate Cox Regression Analyses for OS, BCSS and RFS
Variables OS BCSS RFS
HR 95% CI P HR 95% CI P HR 95% CI P
Age 1.07 1.04-1.09 .000 1.05 1.02-1.09 .003 1.04 1.01-1.07 .012
Lymph node status
- vs. + 2.59 1.30-5.14 .007 5.57 1.85-16.78 .002 6.70 2.52-17.80 .000
Tumor size
>20 vs. ≤20 mm 2.53 1.31-4.89 .006 3.04 1.19-7.78 .02 3.14 1.34-7.10 .006
Ki67 3.00 1.51-5.96 .002 3.99 1.38-11.50 .01 1.68 0.82-3.44 .16
Grade 2.11 1.28-3.49 .004 5.14 2.03-13.00 .001 3.18 1.62-6.25 .001
HER 3.75 1-57-8.99 .003 7.69 2.98-19.86 .000 7.13 3.01-16.90 .000
ER 0.39 0.19-0.79 .009 0.23 0.10-0.55 .001 0.28 0.13-0.60 .001
CD163 in TS 2.66 1.28-5.55 .009 3.20 1.20-8.54 .02 2.12 0.83-5.39 .12
CD68 in TS 0.16 0.07-0.35 .000 15.2 5.45-42.45 .000 9.24 3.64-23.48 .000
CD163 in TN 0.32 0.04-2.37 .27 1.45 0.33-6.32 .62 1.06 0.25-4.55 .94
CD68 in TN 0.05 0.00-21.70 .33 0.44 0.00-169.12 .46 0.04 0.00-43.30 .37
Abbreviations: OS, overall survival; BCSS, breast cancer specific survival; RFS, recurrence free survival; HR, hazard ratio.
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Figure 3 RFS according to the infiltration of CD68+ cells in TS. RFS curve according to the infiltration density of CD68+ cells in TS, A. Gene
expression levels of CD68 in breast cancer patients under endocrine therapy, who were disease-free or who had recurrence, using the microarray
profile set [GenBank:GDS806] [22] from NCBI Gene Expression Omnibus profiles B. ** P<0.01.
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and inversely with luminal A breast cancer. It has previ-
ously been suggested that the amount of TS correlated
with a worse prognosis in triple-negative/basal-like
breast cancer [30]. In our cohort we did not find a cor-
relation between the amount of TS and breast cancer
subtypes, but we found an inverse correlation between
the amount of TS and TS-associated CD163+ and CD68
+ TAMs, rather strengthening the relevance of our find-
ings. Further investigation is needed to understand what
particular factors regulate the recruitment and activation
of TAMs in the different tumor compartments.
Elkabets et al. recently reported that human tumors can
attract GRN expressing hematopoietic cells, which pro-
mote malignancy by activating stromal tissue fibroblasts
[15]. These cells were located in close proximity to fibro-
blasts within the TS in mice. Notably, using the same
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Figure 4 Infiltration of CD163+ cells in different breast cancer subtyp
for patients with luminal A breast cancer A, or triple-negative/basal-like brefound to correlate with the same clinicopathological fea-
tures as CD163+ macrophages in TS [15] as well as with
the density of CD163+ macrophages in TS. This suggests
that the CD163+ macrophages located in TS could repre-
sent GRN+ hematopoietic cells.
Triple-negative/basal-like and luminal A breast can-
cers had different recruitment or differentiation patterns
of CD163+ and CD68+ macrophages in TS. According to
our data, triple-negative/basal-like breast cancers seem
to harbor more CD163+ than CD68+ cells within the TS.
One explanation for the difference between the presence
of CD163+ and CD68+ macrophages in TS among triple-
negative/basal-like breast cancer patients could be that
CD68 is less expressed on mature M2 macrophages or
monocytes. Another explanation could be that CD163
identifies another subset of cells. Although CD163 has
been shown to be a specific monocyte/macrophage mar-
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Table 3 Multivariate Cox Regression Analyses for OS, BCSS and RFS
Variables OS BCSS RFS
HR 95% CI P HR 95% CI P HR 95% CI P
Age 1.07 1.03-1.10 .000 1.05 1.00-1.09 .03 1.03 1.00-1.07 .07
Lymph node status
- vs. + 1.81 0.87-3.82 .12 3.28 1.01-10.63 .05 4.94 1.77-13.80 .002
Tumor size
>20 vs. ≤20 mm 1.58 0.65-3.81 .31 2.47 0.60-10.08 .21 2.12 0.72-6.24 .17
Ki67 3.06 1.05-8.93 .04 4.40 0.67-28.82 .12 0.45 0.13-1.53 .20
Grade 0.63 0.27-1.49 .29 0.86 0.20-3.67 .84 2.25 0.78-6.56 .14
HER 3.45 1.16-10.24 .03 5.37 1.61-17.90 .006 4.46 1.63-12.20 .004
ER 0.47 0.17-1.35 .16 0.39 0.11-1.41 .15 0.37 0.12-1.13 .08
CD163 in TS 0.62 0.24-1.58 .32 0.74 0.23-2.38 .61 0.91 0.30-2.72 .86
CD68 in TS 2.96 0.87-10.11 .08 0.12 0.02-0.72 .02 0.29 0.08-1.10 .07
Abbreviations: OS, overall survival; BCSS, breast cancer specific survival; RFS, recurrence free survival; HR, hazard ratio.
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that the majority of the CD163+ cells are MDCs since
the CD208+ mature MDCs in this breast cancer cohort
were only located in the peri-tumoral T cell rich areas.
However, it cannot be fully excluded that there might be
CD163+ immature myeloid derived cells among the
CD163+ cells in TS. These CD163+ immature myeloid
derived cells could be myeloid derived suppressor cells
which have been shown to enhance tumor progression
by having an immunosuppressive effect on anti-tumor
effectors [31].
Although CD163+ macrophages in TS correlated with
triple-negative/basal-like breast cancer it did not confer
a prognostic value in this group. This could be due to
the small size of the group and their worse overall prog-
nosis, making it difficult to detect any significant differ-
ences in survival. However, it had a prognostic value for
luminal A breast cancer patients.
Interestingly, CD68+ macrophages located in TS posi-
tively correlated with grade, tumor size and inversely
correlated with luminal A breast cancer. It further corre-
lated with poor OS and RFS in the univariate analysis.
More importantly, high density of CD68+ macrophages
in TS was an independent predictor of reduced BCSS.
Even though CD163 and CD68 are expressed on the
same cells and with strong correlations with each other,
our data indicate that they also define immune subpopu-
lations, which affect patient outcome differently and
may therefore have distinct immune functions. In TS,
the broader pan-macrophage marker CD68 had a better
prognostic impact on BCSS compared to the anti-
inflammatory CD163 marker, which is surprising since
CD163 also seems to stain cells of myeloid origin other
than TAMs. CD163+ cells were in particular abundant in
triple-negative/basal-like breast cancer, which was asmall patient group in our TMA. It would therefore be
interesting to see if CD163 would have a prognostic
value in a larger triple-negative/basal-like cohort.Conclusion
Taken together, infiltration of CD163+ and CD68+
macrophages into TS, but not TN, is of clinical rele-
vance for breast cancer patients and highlights the im-
portance of analyzing the localization rather than merely
the presence of TAMs as a prognostic marker. While the
presence of CD163+ macrophages in TS was more
strongly associated with less favorable clinicopathologi-
cal features, CD68+ macrophages in TS was a highly sig-
nificant independent risk factor for a reduced BCSS.Additional files
Additional file 1: Distribution of CD163+ and CD68+ macrophages
in primary breast cancer.
Additional file 2: Correlation between the amount of tumor stroma
content and the density of CD163+ and CD68+ TAMS in TS.
Additional file 3: Correlation between CD163 in tumor stroma and
granulin expression in primary breast cancer.Abbreviations
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